Analysts expect that TG Therapeutics Inc (NASDAQ:TGTX) will post earnings per share of ($0.39) for the current quarter, Zacks reports. Two analysts have provided estimates for TG Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.31). TG Therapeutics posted earnings of ($0.67) per share during the same quarter last year, which would suggest a positive year over year growth rate of 41.8%. The firm is expected to issue its next earnings report on Tuesday, November 10th.
According to Zacks, analysts expect that TG Therapeutics will report full-year earnings of ($1.72) per share for the current fiscal year, with EPS estimates ranging from ($1.93) to ($1.52). For the next financial year, analysts forecast that the firm will report earnings of ($1.17) per share, with EPS estimates ranging from ($2.06) to $0.51. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.15). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 384.84% and a negative net margin of 135,198.03%.
A number of equities research analysts have recently commented on TGTX shares. B. Riley reaffirmed a “buy” rating and issued a $37.00 price objective on shares of TG Therapeutics in a research note on Monday, August 10th. ValuEngine upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, August 3rd. Cantor Fitzgerald raised their price objective on shares of TG Therapeutics from $19.00 to $35.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. HC Wainwright raised their price objective on shares of TG Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Zacks Investment Research downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. TG Therapeutics currently has a consensus rating of “Buy” and an average price target of $39.20.
In other TG Therapeutics news, Director William James Kennedy sold 7,745 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $18.27, for a total transaction of $141,501.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.20% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in TG Therapeutics by 4.8% in the 4th quarter. Bank of New York Mellon Corp now owns 324,590 shares of the biopharmaceutical company’s stock worth $3,602,000 after purchasing an additional 14,901 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in shares of TG Therapeutics by 47.4% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,327 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 3,000 shares during the last quarter. Nuveen Asset Management LLC increased its position in shares of TG Therapeutics by 5.2% during the 4th quarter. Nuveen Asset Management LLC now owns 313,458 shares of the biopharmaceutical company’s stock valued at $3,479,000 after purchasing an additional 15,450 shares during the last quarter. Exane Derivatives increased its position in shares of TG Therapeutics by 4,138.6% during the 1st quarter. Exane Derivatives now owns 18,438 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 18,003 shares during the last quarter. Finally, Centaurus Financial Inc. raised its position in shares of TG Therapeutics by 50.0% during the 1st quarter. Centaurus Financial Inc. now owns 15,000 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 5,000 shares during the period. Hedge funds and other institutional investors own 58.82% of the company’s stock.
NASDAQ TGTX traded up $0.09 on Friday, hitting $23.64. The company’s stock had a trading volume of 26,328 shares, compared to its average volume of 1,511,689. The company has a current ratio of 4.16, a quick ratio of 4.16 and a debt-to-equity ratio of 0.17. TG Therapeutics has a 1-year low of $4.95 and a 1-year high of $24.76. The company’s 50-day moving average is $21.27 and its 200 day moving average is $16.26.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
See Also: Cash Flow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.